
Zenska Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.65 Cr
- Satisfied Charges ₹ 0.50 M
- Revenue Growth 348.96%
- Profit Growth 241.31%
- Ebitda 209.84%
- Net Worth 67.35%
- Total Assets 825.47%
About Zenska Life Sciences
Zenska Life Sciences Private Limited (ZLSPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 26 December 2013 and has a history of 11 years and two months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹3.65 Cr. The company has closed loans amounting to ₹0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Nitin Jain and Hemant Jain serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24233GJ2013PTC125801
- Company No.
032002
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Zenska Life Sciences Private Limited offer?
Zenska Life Sciences Private Limited offers a wide range of products and services, including Vitamins & Supplements, Mineral Supplements, Multivitamins, Protein Supplements, Amino Acids.
Who are the key members and board of directors at Zenska Life Sciences?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Hemant Jain ![]() | Director | 26-Dec-2013 | Current |
Nitin Jain ![]() | Director | 26-Dec-2013 | Current |
Financial Performance of Zenska Life Sciences.
Zenska Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 348.96% increase. The company also saw a substantial improvement in profitability, with a 241.31% increase in profit. The company's net worth Soared by an impressive increase of 67.35%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Zenska Life Sciences?
In 2023, Zenska Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Related Corporates (Common Directorship)
- Evervital Lifesciences Private Limited
Nitin Jain and Hemant Jain are mutual person
- Racion Lifesciences Private Limited
Hemant Jain is a mutual person
Charges (Loans)
₹36.50 M
₹0.50 M
Charges Breakdown by Lending Institutions
- Others : 3.40 Cr
- Indian Bank : 0.25 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
31 Jul 2023 | Others | ₹1.90 Cr | Open |
30 May 2023 | Indian Bank | ₹2.50 M | Open |
26 Apr 2014 | Others | ₹1.50 Cr | Open |
24 May 2018 | Others | ₹0.50 M | Satisfied |
How Many Employees Work at Zenska Life Sciences?
Zenska Life Sciences has a workforce of 50 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Zenska Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zenska Life Sciences's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.